First-line bevacizumab and capecitabine–oxaliplatin in elderly patients with mCRC: GEMCAD phase II BECOX study

BACKGROUND: Subgroup analyses of clinical studies suggest that bevacizumab plus XELOX is effective and tolerable in elderly patients with metastatic colorectal cancer (mCRC). The prospective BECOX study examined the efficacy and safety of bevacizumab plus XELOX, followed by bevacizumab plus capecita...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Feliu, J, Salud, A, Safont, M J, García-Girón, C, Aparicio, J, Vera, R, Serra, O, Casado, E, Jorge, M, Escudero, P, Bosch, C, Bohn, U, Pérez-Carrión, R, Carmona, A, Martínez-Marín, V, Maurel, J
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2014
Assuntos:
Clinical Study
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102952/
https://ncbi.nlm.nih.gov/pubmed/24946000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.346
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares